Prevention and Treatment of Cardiomyopathy and Heart Failure in Patients Receiving Cancer Chemotherapy

Overview

Journal Curr Treat Options Cardiovasc Med

Specialty Cardiology & Vascular Diseases

Date 2008 Nov 26

PMID 19026179

Citations 8

Authors

Daniela Cardinale

Alessandro Colombo

Carlo Maria Cipolla

Affiliations

Soon will be listed here.

Abstract

Chemotherapy (CT)-induced cardiotoxicity remains an unresolved problem that strongly affects the quality of life and overall survival of cancer patients. The most typical form of cardiotoxicity, a dilated cardiomyopathy (CMP), usually becomes manifest late in the course of the disease and is classically considered to be refractory to therapy. Preventing cardiotoxicity remains the most important strategy, and several measures have been proposed, including cardiac function monitoring, limitation of CT dose, use of anthracycline analogues and cardioprotectants, and early detection of cardiotoxicity by biomarkers. The response to modern heart failure therapy of CT-induced CMP has never been evaluated in clinical trials, and no definite guidelines have been adopted. Although it is likely that medications used for other forms of CMP, particularly angiotensin-converting enzyme inhibitors and beta-blockers, may be highly effective, there is still some unjustified concern regarding their use in cancer patients.

Citing Articles

Natural Progression of Left Ventricular Function following Anthracyclines without Cardioprotective Therapy: A Systematic Review and Meta-Analysis.

Lee A, Yau C, Low C, Li J, Tyebally S, Lin W Cancers (Basel). 2023; 15(2).

PMID: 36672461 PMC: 9856944. DOI: 10.3390/cancers15020512.

Transplantation for chemotherapy-induced cardiomyopathy-case series and review of current practice.

Balakrishnan K, Rao K, Subramaniam G, Sharma D Indian J Thorac Cardiovasc Surg. 2020; 36(Suppl 2):287-293.

PMID: 33061213 PMC: 7538490. DOI: 10.1007/s12055-020-01018-8.

Troponins and Natriuretic Peptides in Cardio-Oncology Patients-Data From the ECoR Registry.

Hinrichs L, Mrotzek S, Mincu R, Pohl J, Roll A, Michel L Front Pharmacol. 2020; 11:740.

PMID: 32508657 PMC: 7248256. DOI: 10.3389/fphar.2020.00740.

Chemotherapy-related Cardiomyopathy.

Piper S, McDonagh T Eur Cardiol. 2018; 10(1):19-24.

PMID: 30310418 PMC: 6159418. DOI: 10.15420/ecr.2015.10.01.19.

BNP predicts chemotherapy-related cardiotoxicity and death: comparison with gated equilibrium radionuclide ventriculography.

Skovgaard D, Hasbak P, Kjaer A PLoS One. 2014; 9(5):e96736.

PMID: 24800827 PMC: 4011788. DOI: 10.1371/journal.pone.0096736.

References

Okumura K, Jin D, Takai S, Miyazaki M . Beneficial effects of angiotensin-converting enzyme inhibition in adriamycin-induced cardiomyopathy in hamsters. Jpn J Pharmacol. 2002; 88(2):183-8. DOI: 10.1254/jjp.88.183. View

Othman A, Amer M, El-Missiry M . Potential protective role of angiotensin-converting enzyme inhibitors captopril and enalapril against adriamycin-induced acute cardiac and hepatic toxicity in rats. J Appl Toxicol. 2001; 21(6):469-73. DOI: 10.1002/jat.782. View

Saini J, Rich M, Lyss A . Reversibility of severe left ventricular dysfunction due to doxorubicin cardiotoxicity. Report of three cases. Ann Intern Med. 1987; 106(6):814-6. DOI: 10.7326/0003-4819-106-6-814. View

Ewer M, Vooletich M, Durand J, Woods M, Davis J, Valero V . Reversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response to medical treatment. J Clin Oncol. 2005; 23(31):7820-6. DOI: 10.1200/JCO.2005.13.300. View

Sacco G, Bigioni M, Evangelista S, Goso C, Manzini S, Maggi C . Cardioprotective effects of zofenopril, a new angiotensin-converting enzyme inhibitor, on doxorubicin-induced cardiotoxicity in the rat. Eur J Pharmacol. 2001; 414(1):71-8. DOI: 10.1016/s0014-2999(01)00782-8. View

Haq M, Legha S, Choksi J, Hortobagyi G, Benjamin R, Ewer M . Doxorubicin-induced congestive heart failure in adults. Cancer. 1985; 56(6):1361-5. DOI: 10.1002/1097-0142(19850915)56:6<1361::aid-cncr2820560624>3.0.co;2-s. View

Sparano J, Brown D, Wolff A . Predicting cancer therapy-induced cardiotoxicity: the role of troponins and other markers. Drug Saf. 2002; 25(5):301-11. DOI: 10.2165/00002018-200225050-00001. View

Jensen J, Atar D, Mickley H . Mechanism of troponin elevations in patients with acute ischemic stroke. Am J Cardiol. 2007; 99(6):867-70. DOI: 10.1016/j.amjcard.2006.10.052. View

Adamcova M, Sterba M, Simunek T, Potacova A, Popelova O, Mazurova Y . Troponin as a marker of myocardiac damage in drug-induced cardiotoxicity. Expert Opin Drug Saf. 2005; 4(3):457-72. DOI: 10.1517/14740338.4.3.457. View

10.

Spallarossa P, Garibaldi S, Altieri P, Fabbi P, Manca V, Nasti S . Carvedilol prevents doxorubicin-induced free radical release and apoptosis in cardiomyocytes in vitro. J Mol Cell Cardiol. 2004; 37(4):837-46. DOI: 10.1016/j.yjmcc.2004.05.024. View

11.

Tallaj J, Franco V, Rayburn B, Pinderski L, Benza R, Pamboukian S . Response of doxorubicin-induced cardiomyopathy to the current management strategy of heart failure. J Heart Lung Transplant. 2005; 24(12):2196-201. DOI: 10.1016/j.healun.2004.12.108. View

12.

Tabet J, Meurin P, Ben Driss A, Berthaux X, Weber H, Renaud N . Beta-blockade intolerance in anthracycline-induced cardiomyopathy. Int J Cardiol. 2005; 106(1):132-4. DOI: 10.1016/j.ijcard.2004.12.052. View

13.

Wouters K, Kremer L, Miller T, Herman E, Lipshultz S . Protecting against anthracycline-induced myocardial damage: a review of the most promising strategies. Br J Haematol. 2005; 131(5):561-78. DOI: 10.1111/j.1365-2141.2005.05759.x. View

14.

Silber J, Cnaan A, Clark B, Paridon S, Chin A, Rychik J . Enalapril to prevent cardiac function decline in long-term survivors of pediatric cancer exposed to anthracyclines. J Clin Oncol. 2004; 22(5):820-8. DOI: 10.1200/JCO.2004.06.022. View

15.

Vaynblat M, Shah H, Bhaskaran D, Ramdev G, Davis 3rd W, Cunningham Jr J . Simultaneous angiotensin converting enzyme inhibition moderates ventricular dysfunction caused by doxorubicin. Eur J Heart Fail. 2002; 4(5):583-6. DOI: 10.1016/s1388-9842(02)00091-0. View

16.

Lefrak E, Pitha J, ROSENHEIM S, Gottlieb J . A clinicopathologic analysis of adriamycin cardiotoxicity. Cancer. 1973; 32(2):302-14. DOI: 10.1002/1097-0142(197308)32:2<302::aid-cncr2820320205>3.0.co;2-2. View

17.

Pai V, Nahata M . Cardiotoxicity of chemotherapeutic agents: incidence, treatment and prevention. Drug Saf. 2000; 22(4):263-302. DOI: 10.2165/00002018-200022040-00002. View

18.

Jensen B, Skovsgaard T, Nielsen S . Functional monitoring of anthracycline cardiotoxicity: a prospective, blinded, long-term observational study of outcome in 120 patients. Ann Oncol. 2002; 13(5):699-709. DOI: 10.1093/annonc/mdf132. View

19.

Fazio S, Palmieri E, Ferravante B, Bone F, Biondi B, Sacca L . Doxorubicin-induced cardiomyopathy treated with carvedilol. Clin Cardiol. 1998; 21(10):777-9. PMC: 6655455. DOI: 10.1002/clc.4960211017. View

20.

Telli M, Hunt S, Carlson R, Guardino A . Trastuzumab-related cardiotoxicity: calling into question the concept of reversibility. J Clin Oncol. 2007; 25(23):3525-33. DOI: 10.1200/JCO.2007.11.0106. View